Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | IL1RN | P18510 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635247 | 0.96 | KDM2B (0.41) | KDM2BNAMPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2635298 | 0.88 | KDM2B (0.41) | KDM2BNAMPTSMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL2637346 | 0.87 | KDM2B (0.42) | KDM2BNAMPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2637657 | 0.85 | KDM2B (0.41) | KDM2BLMNASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL2635565 | 0.84 | KDM2B (0.41) | KDM2BSMN1; SMN2ALDH1A1NR3C1CYP3A4 | |
| SCHEMBL2634767 | 0.81 | HTT (0.47) | LMNASMN1; SMN2HTTCYP3A4USP2 | |
| SCHEMBL2635267 | 0.77 | HTT (0.47) | LMNASMN1; SMN2HTTCYP3A4USP2 | |
| SCHEMBL2635511 | 0.76 | MEN1 (0.46) | KDM2BNAMPTTSHRMAPTMEN1 | |
| SCHEMBL2635086 | 0.74 | OTUD7B (0.41) | NAMPTSMN1; SMN2ALDH1A1TSHRCYP3A4 | |
| SCHEMBL2637486 | 0.74 | MEN1 (0.46) | KDM2BLMNATSHRCYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | claimed |
| EP-2569317-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | claimed |
| WO-2011141728-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | claimed |
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | disclosed |
| EP-2569317-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141728-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141728-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109711-A1 | NOVEL COMPOUNDS | TRPV2, CACNA1C, CACNA1B | KDM2B 4602/4885NAMPT 3231/4885LMNA 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.